PHASE I EXPANSION STUDY OF MIRVETUXIMAB SORAVTANSINE, A FOLATE RECEPTOR ALPHA (FRa)-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH ENDOMETRIAL CANCER

被引：0

作者：

Martin, L. ^{[1
]}

Konner, J. ^{[2
]}

O'Malley, D. ^{[3
]}

Bauer, T. ^{[4
]}

Matulonis, U. ^{[5
]}

Seward, S. ^{[6
]}

Oza, A. ^{[7
]}

Kirby, M. ^{[8
]}

Birrer, M. ^{[9
]}

Moore, K. ^{[10
]}

机构：

[1] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[3] Ohio State Univ, Coll Med Obstet & Gynecol, Columbus, OH 43210 USA

[4] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[5] Dana Farber Canc Inst, Gynecol Canc Ctr, Boston, MA 02115 USA

[6] Wayne State Univ, Karmanos Canc Inst, Obstet & Gynecol, Huntington Woods, WV USA

[7] Princess Margaret Canc Ctr, Med, Toronto, ON, Canada

[8] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[9] Massachusetts Gen Hosp, Canc Ctr, Div Gynecol Oncol, Boston, MA 02114 USA

[10] Univ Oklahoma, Stephenson Canc Ctr, Norman, OK 73019 USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2017年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ESGO7-1470

引用

页码：1975 / 1975

页数：1

共 50 条

[1] Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
O'Malley, D.
Richardson, D.
Vergote, I. B.
Gilbert, L.
Martin, L. P.
Mantia-Smaldone, G. M.
Castro, C.
Provencher, D.
Matulonis, U. A.
Malek, K.
Moore, K. N.
ANNALS OF ONCOLOGY, 2019, 30
[2] FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Moore, K.
Oza, A.
Colombo, N.
Oaknin, A.
Scambia, G.
Lorusso, D.
Farias-Eisner, R.
Banerjee, S.
Murphy, C.
Tanyi, J.
Hirte, H.
Konner, J.
Lim, P.
Hayes, M. Prasad
Monk, B.
Kim, S.
Wang, J.
Pautier, P.
Vergote, I.
Birrer, M.
ANNALS OF ONCOLOGY, 2019, 30
[3] Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
O'Malley, David M.
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar M.
Gilbert, Lucy
Vergote, Ignace
Martin, Lainie P.
Mantia-Smaldone, Gina M.
Gonzalez Martin, Antonio
Bratos, Raquel
Penson, Richard T.
Malek, Karim
Moore, Kathleen N.
GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 379 - 385
[4] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients
Martin, L. P.
Konner, J.
Moore, K. N.
Seward, S. M.
Matulonis, U. A.
Perez, R. P.
Zhou, Y.
Ponte, J.
Zhao, J.
Ruiz-Soto, R.
Birrer, M. J.
GYNECOLOGIC ONCOLOGY, 2017, 145 : 34 - 34
[6] Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina M.
Lim, Peter C.
Castro, Cesar M.
Provencher, Diane
Memarzadeh, Sanaz
Method, Michael
Wang, Jiuzhou
Moore, Kathleen N.
O'Malley, David M.
GYNECOLOGIC ONCOLOGY, 2023, 170 : 241 - 247
[7] Initial safety and activity findings froma phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C. M.
Gilbert, L.
Berkenblit, A.
Birrer, M. J.
O'Malley, D. M.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 38 - 38
[8] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Martin, Lainie P.
Konner, Jason A.
Moore, Kathleen N.
Seward, Shelly M.
Matulonis, Ursula A.
Perez, Raymond P.
Su, Ying
Berkenblit, Anna
Ruiz-Soto, Rodrigo
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 402 - 407
[9] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.
O'Malley, David M.
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Zweidler-McKay, Patrick A.
Wang, Jiuzhou
Esteves, Brooke
Moore, Kathleen N.
Gilbert, Lucy
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C.
Gilbert, L.
Malek, K.
Birrer, M. J.
O'Malley, D. M.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →